I built the supplier I couldn’t find.

I started ReVia because I needed a supplier I could trust and couldn’t find one.

In 2019 I was diagnosed with a degenerative neurological disease. Before that I was an entrepreneur and an Ironman triathlete. Conventional medicine didn’t work. I wasted from 180 pounds to 125 and ended up bedridden. One of my doctors suggested I look into peptides.

The market I found sold fakes, underdosed vials, and certificates that were just decoration. I got scammed buying overseas. One vial made me sick, and the same compound from another vendor didn’t. I had no way to know what I was putting in my body, and I decided that wasn’t acceptable for me or for my family.

So I set a standard for anything I’d put in my own body, found a U.S. manufacturer I could walk into and shake hands with, and started supplying it to other people. In July 2026 I said all of this to the FDA’s Pharmacy Compounding Advisory Committee, on the record, five times.

Who he is

Mike Stone spent more than thirty years in business development, corporate finance, biotechnology, medtech, pharma and real estate, from startup to growth stage, including companies that sat between pharmaceutical and consumer markets. He was an entrepreneur and an Ironman triathlete. In 2019 he was diagnosed with a degenerative neurological disease. Conventional medicine did not work. He went from 180 pounds to 125 and was bedridden.

Why he was in the room

Physicians at one of the country’s leading institutions suggested he explore peptides, and he did it the way everyone does: Reddit, podcasts, strangers who knew a guy. He bought overseas and got scammed. One vial of TB-500 gave him hot flashes, nausea and welts at the injection site; the same compound from another vendor did nothing of the kind. That taught him that every supplier is different and a good review proves nothing. He decided that if he was going to put something in his body, he would know exactly what it was, and the same for his family. He found a US-based manufacturer he could visit, walk through and shake hands with, and started ReVia in Fort Myers, Florida. When FDA took seven peptides to its Pharmacy Compounding Advisory Committee on July 23–24, 2026, he filed a written comment to the docket as owner of ReVia LLC, registered for the open public hearing, and spoke five times from the podium at White Oak. He told the committee his market was gray, that he was in it, and that he wanted it regulated. The committee recommended six of the seven.